Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.37 |
| ▸ | GLMN | Q92990 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 4/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507694 | 0.82 | ALDH1A1 (0.46) | DPP9DPP8NAMPTCALCRLMAPT | |
| SCHEMBL6426012 | 0.81 | TSHR (0.50) | TSHRMAPTHTTNPSR1ALDH1A1 | |
| SCHEMBL6428167 | 0.81 | HSP90AA1 (0.39) | DPP9DPP8GLMNNAMPTTSHR | |
| SCHEMBL6430640 | 0.80 | ALDH1A1 (0.40) | TSHRMAPTHTTNPSR1ALDH1A1 | |
| SCHEMBL6428776 | 0.78 | ALDH1A1 (0.49) | DPP8MAPTHTTNPSR1ALDH1A1 | |
| SCHEMBL6427696 | 0.78 | DPP8 (0.34) | DPP9DPP8GLMNNAMPTTSHR | |
| SCHEMBL6393517 | 0.77 | ALDH1A1 (0.55) | DPP8MAPTHTTNPSR1ALDH1A1 | |
| SCHEMBL6500205 | 0.77 | DPP9 (0.46) | DPP9DPP8GLMNALDH1A1 | |
| SCHEMBL6386550 | 0.76 | NAMPT (0.42) | DPP9DPP8NAMPTMAPTALDH1A1 | |
| SCHEMBL6427188 | 0.76 | ALDH1A1 (0.57) | DPP8TSHRMAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | DPP9 1066/4885DPP8 1825/4885GLMN 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.